Brøsen K.Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics . Clinical Pharmacokinetics1990; 18: 220-39.
2.
Sjöqvist F.Slow drug hydroxylation: Implications for patient management and drug utilization . In: Xenobiotic Metabolism and Disposition, Proceedings of the 2nd International ISSX Meeting, Kobe, Japan, May 16-20, R. Kato, R.W. Estabrook and M.N. Cayen (eds), London, Taylor & Francis, 1989, pp. 475-82.
3.
Dahl-Puustinen ML, Lidén A., Alm C., Nordin C. & Bertilsson L.Disposition of perphenazine is related to the polymorphic debrisoquine hydroxylation in human beings. Clinical Pharmacology and Therapeutics1989; 46: 78-81.
4.
Siddoway LA, Thompson KA, McAllister CB et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation1987; 75: 785-91.
5.
Beckmann J., Hertrampf R., Gundert-Remy U., Mikus G., Gross AS & Eichelbaum M.Is there a genetic factor in flecainide toxicity?British Medical Journal1988; 297: 1396.
6.
Lledó P., Abrams Sml, Johnston A. & Pearson RMMexiletine pharmacokinetics and debrisoquine hydroxylator status. EuropeanJournal of Pharmacology1990; 183: 2387.
7.
Funck-Brentano C., Kroemer HK, Pavlou H., Woosley, RL & Roden DMGenetically determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. British Journal of Clinical Pharmacology1989; 27: 435-444.
8.
Lledó-Polo MP , PhD Thesis, University of London, 1991.
9.
Lennard MS, Silas JH, Smith AJ & Tucker GTDetermination of debrisoquine and its 4-hydroxymetabolite in biological fluids by gas chromatography with flame ionization and nitrogen-selective detection . Journal of Chromatography1977; 177: 161-166.
10.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine1989; 321: 406-12.
